US 11,918,605 B1
Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancer
Samuel C. Wagner, San Diego, CA (US); Thomas E. Ichim, San Francisco, CA (US); Julia S. Szymanski, San Diego, CA (US); Santosh Kesari, San Diego, CA (US); Amit N. Patel, Salt Lake City, UT (US); and Boris Minev, San Diego, CA (US)
Assigned to MYELOID THERAPEUTICS, INC., Cambridge, MA (US)
Filed by Myeloid Therapeutics, Inc., Cambridge, MA (US)
Filed on Oct. 27, 2022, as Appl. No. 17/975,187.
Application 17/975,187 is a continuation of application No. 17/715,558, filed on Apr. 7, 2022, granted, now 11,517,589.
Application 17/715,558 is a continuation of application No. 17/559,967, filed on Dec. 22, 2021.
Application 17/559,967 is a continuation of application No. 17/227,193, filed on Apr. 9, 2021, abandoned.
Application 17/227,193 is a continuation of application No. 15/048,922, filed on Feb. 19, 2016, abandoned.
Claims priority of provisional application 62/118,027, filed on Feb. 19, 2015.
Int. Cl. A61K 35/15 (2015.01); A61K 38/17 (2006.01); C07K 16/00 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01); C12N 5/0786 (2010.01)
CPC A61K 35/15 (2013.01) [A61K 38/177 (2013.01); C07K 16/00 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); C12N 5/0645 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C12N 2501/599 (2013.01); C12N 2510/00 (2013.01)] 30 Claims
 
1. A pharmaceutical composition comprising:
(a) an ex vivo population of cells comprising CD14+/CD16+ cells, wherein the CD14+/CD16+ cells comprise a recombinant polynucleic acid with a sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises (i) an anti-HER2/neu binding domain and a CD8a hinge domain; (ii) a transmembrane domain; and (iii) an intracellular domain containing a CD3 zeta intracellular signaling domain; and
(b) a pharmaceutically acceptable excipient;
wherein the pharmaceutical composition stimulates tumor killing by T cells in a subject with cancer when the pharmaceutical composition is administered to the subject.